Factor xi-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis

Infection and Immunity

Volumn 80, Issue 1, 2012, Pages 91-99

  Luo, Deyan ^a   Szaba, Frank M ^a   Kummer, Lawrence W ^a   Johnson, Lawrence L ^a   Tucker, Erik I ^b   Gruber, Andras ^b   Gailani, David ^c   Smiley, Stephen T ^a  

^a TRUDEAU INSTITUTE   (United States)

^b Oregon Health and Science University Department of Biomedical Engineering   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; FIBRIN; INTERLEUKIN 10; INTERLEUKIN 6; ANTIBODY; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 11 DEFICIENCY; CONTROLLED STUDY; CYTOKINE PRODUCTION; INFLAMMATION; LISTERIA MONOCYTOGENES; LISTERIOSIS; LIVER NECROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; ANIMAL; C57BL MOUSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COMBINATION; GROWTH, DEVELOPMENT AND AGING; LIVER; MICROBIOLOGY; MORTALITY; MOUSE MUTANT; PATHOGENICITY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG THERAPY, COMBINATION; FACTOR XI DEFICIENCY; INFLAMMATION; LISTERIA MONOCYTOGENES; LISTERIOSIS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857086204     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05568-11     Document Type: Article

References (44)

1. Angus DC, et al. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
2. Ansell J. 2007. Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemost. 5(Suppl. 1):60-64.
3. Bakker-Woudenberg IA, de Bos P, van Leeuwen WB, Michel MF. 1981. Efficacy of ampicillin therapy in experimental listeriosis in mice with impaired T-cell-mediated immune response. Antimicrob. Agents Chemother. 19:76-81.
4. Bernard GR, et al. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709.
5. Bone RC, et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest 101:1644-1655.
6. Cheng Q, et al. 2010. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 116:3981-3989.
7. Dejager L, Pinheiro I, Dejonckheere E, Libert C. 2011. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 19:198-208.
8. Dyson A, Singer M. 2009. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit. Care Med. 37:S30-S37.
9. Franco RF, et al. 2000. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 96:554-559.
10. Furie B, Furie BC. 1988. The molecular basis of blood coagulation. Cell 53:505-518.
11. Gailani D, Broze GJ, Jr. 1991. Factor XI activation in a revised model of blood coagulation. Science 253:909-912.
12. Gailani D, Lasky NM, Broze GJ, Jr. 1997. A murine model of factor XI deficiency. Blood Coagul. Fibrinolysis 8:134-144.
13. Gailani D, Renne T. 2007. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J. Thromb. Haemost. 5:1106-1112.
14. Jansen PM, et al. 1996. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87:2337-2344.
15. Johnson LL, Berggren KN, Szaba FM, Chen W, Smiley ST. 2003. Fibrin-mediated protection against infection-stimulated immunopathology. J. Exp. Med. 197:801-806.
16. Kerschen EJ, et al. 2007. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J. Exp. Med. 204:2439-2448.
17. Kinasewitz GT, et al. 2004. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit. Care 8:R82-R90.
18. Levi M. 2008. Activated protein C in sepsis: a critical review. Curr. Opin. Hematol. 15:481-486.
19. Levi M. 2007. Disseminated intravascular coagulation. Crit. Care Med. 35:2191-2195.
20. Levi M, Van Der Poll T. 2004. Coagulation in sepsis: all bugs bite equally. Crit. Care 8:99-100.
21. Levi M, van der Poll T. 2010. Inflammation and coagulation. Crit. Care Med. 38:S26-S34.
22. Marti-Carvajal AJ, Sola I, Lathyris D, Cardona AF. 2011. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst. Rev. 4:CD004388.
23. Minnema MC, et al. 1998. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood 92:3294-3301.
24. Morser J, Gabazza EC, Myles T, Leung LL. 2010. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J. Thromb. Haemost. 8:868-876.
25. Mullarky IK, et al. 2005. Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis. Infect. Immun. 73:3888-3895.
26. Naito K, Fujikawa K. 1991. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J. Biol. Chem. 266:7353-7358.
27. Oehmcke S, Herwald H. 2010. Contact system activation in severe infectious diseases. J. Mol. Med. 88:121-126.
28. Oehmcke S, et al. 2009. Treatment of invasive streptococcal infection with a peptide derived from human high-molecular weight kininogen. Blood 114:444-451.
29. Pamer EG. 2004. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4:812-823.
30. Pawlinski R, Mackman N. 2010. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb. Res. 125(Suppl. 1):S70-S73.
31. Pixley RA, et al. 1993. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J. Clin. Invest. 91:61-68.
32. Renne T, et al. 2009. Factor XI deficiency in animal models. J. Thromb. Haemost. 7(Suppl. 1):79-83.
33. Riedemann NC, Guo RF, Ward PA. 2003. The enigma of sepsis. J. Clin. Invest. 112:460-467.
34. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. 2002. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296:1880-1882.
35. Seligsohn U. 2009. Factor XI deficiency in humans. J. Thromb. Haemost. 7(Suppl. 1):84-87.
36. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. 2011. The pathogenesis of sepsis. Annu. Rev. Pathol. 6:19-48.
37. Suh TT, et al. 1995. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9:2020-2033.
38. Tapper H, Herwald H. 2000. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood 96:2329-2337.
39. Tilley R, Mackman N. 2006. Tissue factor in hemostasis and thrombosis. Semin. Thromb. Hemost. 32:5-10.
40. Tucker EI, et al. 2008. Survival advantage of coagulation factor XIdeficient mice during peritoneal sepsis. J. Infect. Dis. 198:271-274.
41. van Gorp EC, et al. 2001. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br. J. Haematol. 113:94-99.
42. von dem Borne PA, Meijers JC, Bouma BN. 1995. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86:3035-3042.
43. Weitz JI, Linkins LA. 2007. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin. Invest. Drugs 16:271-282.
44. Wing EJ, Gregory SH. 2002. Listeria monocytogenes: clinical and experimental update. J. Infect. Dis. 185(Suppl. 1):S18-S24.